COVAX, the ACT-Accelerator’s Vaccines Pillar is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, the World Health Organization (WHO) and UNICEF as key implementing partner, and with vaccine manufacturers, civil society organizations and the World Bank.
Delivered almost 2 billion vaccine doses by December 2022
Helped more than 40 countries start their vaccination campaigns
Doubling the coverage rate in AMC92 countries during 2022 to 52% average coverage
Contribute to countries’ national vaccination objectives in light of the WHO target of 70% coverage in all countries by mid-2022
IMPACT STORY: 190 MILLION VACCINE DOSES DELIVERED THROUGH COVAX IN BANGLADESH
In one year, UNICEF has delivered over 190 million doses of COVID-19 vaccines to Bangladesh through COVAX. To date, Bangladesh remains the top recipient of doses under COVAX, the global initiative co-led by CEPI, Gavi and the World Health Organization, with UNICEF as a key delivery partner. COVAX accounts for more than 62% of doses received by the country. The goal of COVAX is to ensure equitable access of COVID-19 vaccines globally.
COVID-19 vaccinations started in Bangladesh in February 2021. UNICEF delivered the first COVAX shipment of vaccines to Bangladesh on 1 June 2021, at a time when only 4 per cent of the population in the country were fully vaccinated. A year on, thanks to a strong partnership between the Government, the World Health Organization, UNICEF and other partners, Bangladesh has fully vaccinated with two doses 69 per cent of its population – a staggering 117 million people.
COVID-19 VACCINE DELIVERY PARTNERSHIP
In January 2022, WHO, UNICEF and Gavi established the COVID-19 Vaccine Delivery Partnership to support vaccine delivery.
It specifically provides urgent operational support to the 34 countries that were at or below 10% full vaccination coverage in January 2022 to progress towards national and global targets.
The greatest benefits of this approach will come from prioritizing full vaccination and boosters for high-priority populations – older adults, healthcare workers, and persons with co-morbidities including immunocompromised persons.